Petros Pharmaceuticals Inc (PTPI) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Petros Pharmaceuticals Inc $0.00, price $0.00, upside +0.0%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Petros Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $0.0025 – $1,023 · fair‑value band $0.0034 – $0.0036 · the $0.0035 price screens below the $0.0035 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Petros Pharmaceuticals in your weekly email
Every Wednesday you see whether Petros Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary software as a service (SaaS) platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.
Stock analysis
Petros Pharmaceuticals Inc (PTPI) currently trades at $0.0035, while our model-based Fair Value estimate is $0.0035, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $0.0032 per share, and 3 of the 6 models we run sit above the $0.0035 price.
Bear case: the Earnings-Based group reads lowest at $0.0016, and 3 of the 6 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0034 (bear) to $0.0036 (bull), the price of $0.0035 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Petros Pharmaceuticals Inc reported revenue of $0 in FY2025 versus $7.8M in FY2021. Reported net income was $1.9M in FY2025.
Key figures
Market cap $254K · P/E ratio 0.0 · P/S ratio 0.05 · EPS (TTM) $6.64 · Return on equity −565% · Return on assets (EBIT) −59.0% · Revenue (TTM) $5.1M · Revenue growth (YoY) −5.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 86% below its 52-week high and 40% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 0%, PTPI screens cheaper than that median.
Fair Value models
Bear $0.0034Fair Value $0.0035Bull $0.0036
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($5.00 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.5/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−12.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.0%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.5%
’18
’19
’20
’21
’22
’23
’24
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−124.0% (2019) → −345.8% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Compare Petros Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 600 stocks
Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside+2.9% · Above median
Profitability
Return on assets−23.9% · Bottom 25%
Operating margin (TTM)0.0% · Below median
Growth and dividend
Revenue growth−5.9% · Below median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Petros Pharmaceuticals Inc (PTPI) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0035 versus a price of $0.0035, about +0% upside (fairly valued).
What is the fair value of PTPI?
Our model-based fair value for Petros Pharmaceuticals Inc is $0.0035 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.0035.
What is the quality score of PTPI?
Petros Pharmaceuticals Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Petros Pharmaceuticals Inc (PTPI)?
Our model-based price target is the fair value of $0.0035 (as of Sep 27, 2026) from 6 valuation models. Cautious scenario $0.0034, optimistic scenario $0.0036. It is a calculation from audited fundamentals, not an analyst target.
What is the Petros Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $0.0035, about +0% upside versus a price of $0.0035 (fairly valued). Cautious scenario $0.0034, optimistic scenario $0.0036. The calculation is refreshed regularly with new filings.
What is the revenue of Petros Pharmaceuticals Inc (PTPI)?
Petros Pharmaceuticals Inc reported trailing-twelve-month revenue of about $5.1M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Petros Pharmaceuticals Inc (PTPI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Petros Pharmaceuticals Inc it is $0.0035 per share (as of Sep 27, 2026), against a price of $0.0035. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is Petros Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, PTPI trades below its calculated fair value: price $0.0035, fair value $0.0035, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PTPI?
No. The price is what the market pays today ($0.0035); the fair value is what the company's own numbers justify ($0.0035). For Petros Pharmaceuticals Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Petros Pharmaceuticals Inc worth?
The market values Petros Pharmaceuticals Inc at about $254K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0035; our models calculate a fair value of $0.0035 per share.
What do the bullish and bearish scenarios say about PTPI?
Our models span a range for Petros Pharmaceuticals Inc: cautious scenario $0.0034, base $0.0035, optimistic $0.0036 per share (as of Sep 27, 2026, price $0.0035). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PTPI?
Petros Pharmaceuticals Inc trades at a price-to-earnings ratio of 0.0 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.0035 is built from several models across several years. Other multiples: P/S 0.1.
How solid is the balance sheet of Petros Pharmaceuticals Inc (PTPI)?
Balance-sheet figures for Petros Pharmaceuticals Inc (as of Sep 27, 2026): debt of 0.00 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is PTPI from its 52-week high?
Petros Pharmaceuticals Inc trades at $0.0035, about 86% below its 52-week high of $0.0250 and 40% above the low of $0.0025 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0035 is for.
Which stocks are comparable to Petros Pharmaceuticals Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Petros Pharmaceuticals Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0035, calculated fair value $0.0035 (+0%), Quality Score 32/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PTPI calculated?
We run Petros Pharmaceuticals Inc through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0035, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Petros Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Petros Pharmaceuticals Inc (PTPI)?
The closing price on Oct 2, 2026 was $0.0035. Our model-based fair value is $0.0035, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Petros Pharmaceuticals Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0034 to $0.0036), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Petros Pharmaceuticals Inc
How large is the market capitalisation of Petros Pharmaceuticals Inc (PTPI)?
The market capitalisation of Petros Pharmaceuticals Inc is $254K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Petros Pharmaceuticals Inc (PTPI)?
The price-to-sales ratio of Petros Pharmaceuticals Inc is 0.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Petros Pharmaceuticals Inc (PTPI)?
Earnings per share at Petros Pharmaceuticals Inc are $6.64 (price ÷ EPS = P/E 0.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Petros Pharmaceuticals Inc (PTPI)?
The return on equity (ROE) of Petros Pharmaceuticals Inc is −565% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Petros Pharmaceuticals Inc (PTPI)?
On an EBIT basis the return on assets of Petros Pharmaceuticals Inc is −59.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Petros Pharmaceuticals Inc (PTPI)?
Revenue at Petros Pharmaceuticals Inc is growing −5.9% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Petros Pharmaceuticals Inc (PTPI) generate?
The free cash flow of Petros Pharmaceuticals Inc is −$6.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Petros Pharmaceuticals Inc (PTPI) hold?
Petros Pharmaceuticals Inc holds more cash than debt, $5.1B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Petros Pharmaceuticals Inc in the live analysis
One click puts Petros Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026